Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea

Journal of Drugs in Dermatology

Volumn 12, Issue 3, 2013, Pages 292-298

  Jackson, J Mark ^a   Lorenz, Douglas J ^b   Kircik, Leon H ^c,d,e  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY   (United States)

^e Physicians Skin Care PLLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; MINOCYCLINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DERMATOLOGIST; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; ERYTHEMA; FACE; FEMALE; FLUSHING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PAPULE; PUSTULE; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SCORING SYSTEM; SKIN EDEMA; SKIN NODULE; STOMACH UPSET; SUSTAINED DRUG RELEASE; TELANGIECTASIA; UNITED STATES; URTICARIA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; DELAYED-ACTION PREPARATIONS; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MINOCYCLINE; ROSACEA; TREATMENT OUTCOME;

EID: 84874613439     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Abram K, Silm H, Oona M. Prevalence of rosacea in an Estonian working population using a standard classification. Acta Derm Venereol. 2010;90(3):269-273.
2. National Rosacea Society Web site. What is rosacea? http://www.rosacea. org/index.php. Accessed April 19, 2010.
3. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20(3):199-206. (Pubitemid 32927782)
4. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. 2008;122(2):261-266.
5. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327-341. (Pubitemid 39178655)
6. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499-512.
7. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584-587.
8. Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc). 2007;43(1):27-34. (Pubitemid 46448835)
9. Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12(2):1-5, 9.
10. Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63(2):130-145.
11. Fleischer AB Jr, Dinehart S, Stough D, Plott RT; Solodyn Phase 2 Study Group; Solodyn Phase 3 Study Group. Safety and efficacy of a new extended- release formulation of minocycline. Cutis. 2006;78(4 Suppl):21-31. (Pubitemid 44720406)
12. Stewart DM, Torok HM, Weiss JS, Plott RT; Solodyn Phase 2 Study Group. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006;78(4 Suppl):11-20. (Pubitemid 44720405)
13. 15% azelaic acid [package insert]. Pine Brook, NJ: Intendis, Inc; 2007.
14. Del Rosso JQ, Baum EW, Draelos ZD, et al. Azelaic acid gel 15%: clinical versatility in the treatment of rosacea. Cutis. 2006;78(5 Suppl):6-19. (Pubitemid 44952086)